4/26
02:07 am
apre
Interim Report - January-March 2024 [Yahoo! Finance]
Low
Report
Interim Report - January-March 2024 [Yahoo! Finance]
4/10
12:11 pm
apre
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 [Yahoo! Finance]
4/10
12:00 pm
apre
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Medium
Report
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
3/27
08:07 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its price target raised by analysts at Wedbush from $9.00 to $11.00. They now have an "outperform" rating on the stock.
Low
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its price target raised by analysts at Wedbush from $9.00 to $11.00. They now have an "outperform" rating on the stock.
3/26
11:13 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
3/26
07:55 am
apre
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
Low
Report
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
3/26
07:45 am
apre
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Low
Report
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
3/14
07:53 am
apre
Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million [Yahoo! Finance]
Medium
Report
Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million [Yahoo! Finance]
3/11
08:52 am
apre
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers [Yahoo! Finance]
High
Report
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers [Yahoo! Finance]
3/11
08:52 am
apre
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million [Yahoo! Finance]
High
Report
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million [Yahoo! Finance]
3/11
08:30 am
apre
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
High
Report
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
3/11
08:29 am
apre
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
Medium
Report
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
3/5
04:56 pm
apre
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 [Yahoo! Finance]
3/5
04:45 pm
apre
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Low
Report
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
2/6
08:19 am
apre
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor [Yahoo! Finance]
High
Report
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor [Yahoo! Finance]
2/6
08:01 am
apre
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
High
Report
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
1/30
08:10 am
apre
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 [Yahoo! Finance]
Low
Report
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 [Yahoo! Finance]
1/30
08:00 am
apre
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
Low
Report
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024